• AtCor Medical (West Ryde, Australia) reported that Duncan Ross will become CEO of the company at the annual general meeting on Nov. 9. Ross will succeed Ross Harricks, the co-founder of AtCor, who will remain an executive director of the company, focusing on corporate and technology development. Ross is currently president/CEO of AtCor’s North American business. Prior to joining AtCor, he was president of Apogent Technologies and Fisher Scientific Products laboratory equipment group. Atcor is developer of the SphygmoCor device, a non-invasive system that provides calibrated blood pressure waveform in the ascending aorta.

• David Elizondo has been named vice president, research and development for ATS Medical (Minneapolis). Previously, Elizondo was director, new business development at Boston Scientific. ATS makes products focused on cardiac surgery.

• James Buck has been named vice president, marketing and business development for InnerPulse (Research Triangle Park, North Carolina). Buck most recently was vice president, marketing and business development for Closure Medical. Before joining Closure, Buck spent 11 years at St. Jude Medical. InnerPulse is an early-stage company developing the Percutaneous Implantable Cardioverter Defibrillator (PICD).

• Raoul Bonan, MD, an interventional cardiologist, has been named a clinical consultant for MIV Therapeutics (Atlanta) to oversee the next phases of MIVT’s research and human clinical studies. Bonan during his career has helped develop and obtain FDA approval for several interventional cardiac devices, including one of the first PTCA balloons, MIVT said. MIVT develops next-generation cardiovascular stent technology based on its proprietary hydroxyapatite (HAp) technology.

• Elvira Lang, MD, has been named vice president and chief medical officer for OmniSonics Medical Technologies (Wilmington, Massachusetts). Lang most recently served as chief of vascular/interventional radiology at the Beth Israel Deaconess Medical Center. In 1999 she was appointed Associate Professor of Radiology at Harvard Medical School. OmniSonics is a venture-backed company focused on developing products to treat vascular occlusive disease. Its first product, the Resolution System, is based on its OmniWave Technology for delivery of low-power acoustic energy around the active length of a small diameter wire in a diseased blood vessel.